The short answer: breast cancer in women under 40 is rare, but it is increasing in many countries and presents unique challenges. Young women are more likely to be diagnosed at later stages, with more aggressive tumour subtypes, including triple-negative and HER2-positive disease [1][8][9]. They face distinct concerns around fertility preservation, pregnancy after treatment, and long-term quality of life [3][11][15]. Survival outcomes vary dramatically depending on where a woman lives: over 90% in high-income countries, compared with around 40% in some low- and middle-income countries [1].
Breast cancer is often thought of as a disease of older women. That perception is partly correct: most cases occur after menopause. But a significant number of women are diagnosed before their 40th birthday, and their experience of the disease is different in several important ways.
This article explains what the latest research shows about early-onset breast cancer, why it presents differently, and what it means for young women across Africa, Asia, and beyond.
How common is breast cancer in young women?
Breast cancer diagnosed under age 40, sometimes called early-onset breast cancer (EOBC), accounts for a minority of all breast cancer cases. In high-income countries, the age-standardised incidence rate in women under 40 is very low, often only a few cases per 100,000 women [1].
But the picture varies by region. A 2026 review in Critical Reviews in Oncology/Hematology found that in low- and middle-income countries (LMICs), the incidence in women under 40 is higher than in high-income countries [1]. African countries in particular had the highest breast cancer mortality relative to incidence in women under 40, while Europe and North America had much lower ratios [1].
The trends are concerning. A meta-analysis of data from the United States, Europe, and Asia found that breast cancer incidence and mortality have increased among women younger than 45 across all three regions [9]. In the United States, incidence rose by 0.7% annually from 2001 to 2022, with faster increases in women under 50 (1.4% per year) than in older women (1.0% per year). Distant-stage (metastatic) breast cancer among women aged 20 to 39 rose by more than 4% annually since 2000 [9].
In Asia, incidence among women aged 16 to 40 increased from 2.28 to 4.26 per 100,000 between 1970 and 2002 [9].
Why young women face a different challenge
Several factors make breast cancer in young women distinct from the disease in older women.
Later stage at diagnosis
Young women are not routinely screened for breast cancer. Screening programmes typically begin at age 40 or 50. This means cancers in younger women are usually found when they cause symptoms, which often means they are larger and more advanced [1][10].
A 2024 study in Ghana compared young premenopausal women (under 35) with postmenopausal women. Among the younger group, 80.7% had stage III or IV disease at diagnosis. Among postmenopausal women, 87.0% had stage III or IV disease [7]. Both groups presented late, but the young women were not protected by screening because none exists for their age group.
A 2026 study from Uruguay found that 28.7% of young women presented with stage III disease, and invasive ductal carcinoma was the predominant histology (85.8%) with a high proportion of grade III tumours (39.3%) [16].
More aggressive tumour biology
Young women are more likely to develop aggressive subtypes of breast cancer. A 2024 review in The Breast noted that young women are more likely to be diagnosed with high-grade tumours and that more than half have tumours that do not express the progesterone receptor [10].
A transcriptomic study found that young patients (under 45) had four-fold more basal tumours compared with women aged 45 to 65. The study also found that young African patients had a higher tendency to develop basal tumours, while young Asian patients were more prone to luminal A tumours [6].
In the Ghanaian study, both young premenopausal and postmenopausal women had a high prevalence of triple-negative breast cancer: 64.5% and 64.4% respectively [7]. This is much higher than the rates seen in Caucasian populations.
Higher prevalence of genetic mutations
About half of early-onset breast cancers are related to BRCA1 and BRCA2 mutations [2]. Other genes including PALB2 and TP53 also increase risk for early-onset disease [2][18].
Dana-Farber notes that around 10% of young adults with breast cancer carry a BRCA1 or BRCA2 mutation, and these mutations can raise lifetime breast cancer risk to 50% to 85% [18]. The high prevalence of genetic mutations in young women has implications for genetic testing and for family members who may also be at risk.
The fertility question
For many young women, the most urgent concern after a breast cancer diagnosis is whether they will be able to have children.
Chemotherapy can damage the ovaries and may cause temporary or permanent infertility. The risk depends on the woman’s age, the drugs used, and the dose [11].
Several options exist to preserve fertility before treatment begins [19]:
- Egg or embryo freezing (cryopreservation): Eggs or fertilised embryos are collected and stored for future use. This process can take several weeks and may require hormone stimulation.
- Ovarian tissue freezing: A minimally invasive procedure removes egg-containing ovarian tissue, which is frozen and later reimplanted. This option can be used before or after puberty, and for women who cannot take hormone-stimulating medications.
- Ovarian suppression therapy: Injections of GnRH agonists put the ovaries into a dormant state during chemotherapy, protecting them from damage. Studies show women receiving this treatment are more likely to have healthy pregnancies later [11].
A 2025 study in Ghana found that fertility preservation awareness among young breast cancer patients was only 39.3%. Major barriers included cost (73.5%), fear (50%), and partner objection (14.3%) [15]. The authors concluded that integrating fertility counselling into cancer care could improve outcomes for young patients.
The POSITIVE trial addressed the question of whether women with hormone-sensitive breast cancer can safely pause endocrine therapy to pursue pregnancy. The trial enrolled 518 women aged 42 or younger. Results published in the New England Journal of Medicine in 2023 showed that pausing therapy for up to two years did not increase short-term recurrence risk. Updated data presented at ESMO 2025 confirmed these results, with recurrence rates of 12.3% among women who paused therapy compared with 13.2% in similar cohorts. In total, 76% of participants became pregnant, and 440 babies were born [3].
Quality of life and survivorship
Young women with breast cancer face distinct quality-of-life challenges that extend beyond the physical effects of treatment.
A 2025 study from Mexico followed 477 women aged 40 or younger for five years after diagnosis. Most patients (62%) were classified as having a “poor” quality-of-life trajectory. The most affected domains were sexual enjoyment, which declined from 51.0 to 37.3 in the poor group, and future perspective, which remained lower than in the good group [13].
A 2025 clinical trial tested a mobile health tool called Young, Empowered, and Strong (YES) for young breast cancer survivors. The tool delivers tailored information and support based on patient-reported outcomes. After six months, participants using YES showed significantly greater improvement in both general and cancer-specific quality of life compared with those receiving usual care. Arm and vaginal symptoms also improved significantly [5].
The researchers described the findings as paradigm-changing because most interventions using patient-reported outcomes have required high-touch clinician interaction. YES showed that a low-touch intervention with limited clinician input can improve outcomes [5].
The global divide in outcomes
The most striking feature of early-onset breast cancer is how much survival depends on where a woman lives.
A 2026 review in Critical Reviews in Oncology/Hematology found that in high-income countries, organised screening programmes, widespread use of advanced imaging, timely diagnosis, and access to modern treatments contribute to survival rates exceeding 90% [1].
In contrast, the WHO reports that five-year survival is approximately 66% in India and around 40% in South Africa [1]. Women in LMICs often face delayed diagnoses, limited diagnostic tools, and restricted access to surgery, radiotherapy, and targeted therapies [1][8].
A 2026 review noted that the disparities are rooted in unequal access to early detection, essential treatments, and supportive care. Factors including lack of awareness, inadequate pathology services, and the high cost of treatment further deepen these gaps [8].
A 2026 consensus from China highlighted that the incidence of breast cancer in young women is increasing globally, especially in China. The consensus emphasised that young patients face a high risk of recurrence and metastasis, along with unique needs related to fertility, psychological well-being, and return to work [4].
What is myth, not documented
Myth: Young women do not get breast cancer. Breast cancer can occur at any age, even in adolescence and young adulthood. While rare, it is a leading cause of cancer-related mortality among young adult women [2][9].
Myth: Pregnancy after breast cancer increases the risk of recurrence. The evidence does not support this. The POSITIVE trial showed that pausing endocrine therapy to pursue pregnancy did not increase short-term recurrence risk [3]. Yale experts note that the assumption that pregnancy stimulates recurrence has been disproven [11].
Myth: Fertility preservation is too expensive or unavailable. Cost is a real barrier, especially in LMICs [15]. But options exist, and many can be integrated into cancer care before treatment begins [19].
The bottom line
Breast cancer in young women is a different challenge from the disease in older women. It presents at later stages, with more aggressive biology and a higher prevalence of genetic mutations. Young women face urgent questions about fertility and long-term quality of life. And their survival depends heavily on where they live, with a gap of more than 50 percentage points between high-income and low-income countries [1].
Addressing these disparities requires earlier detection, better access to treatment, and care that addresses the specific needs of young women, including fertility preservation and psychosocial support. The evidence shows that progress is possible, but it is not yet reaching everyone who needs it.
Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. If you have concerns about breast cancer or your risk, consult a qualified healthcare provider. We welcome your feedback and corrections. Please contact us if you notice any errors.
References
[1] Disparities in diagnosis, treatment, and outcomes of early-onset breast cancer: A global perspective, ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S1040842826001381
[2] How young can you get breast cancer?, MD Anderson Cancer Center. https://www.mdanderson.org/cancerwise/how-young-can-you-get-breast-cancer.h00-159778812.html
[3] What have we achieved for women with breast cancer so far?, IBCSG. https://www.ibcsg.org/en/support-contact/achievements
[4] Expert consensus on the diagnosis and treatment of young breast cancer in China (2026 edition), Chinese Medical Journal. https://rs.yiigle.com/cmaid/1688196
[5] Mobile Health Tool Helps Improve Quality of Life For Young Breast Cancer Survivors, Dana-Farber Cancer Institute. https://physicianresources.dana-farber.org/news/mobile-health-tool-helps-improve-quality-of-life-for-young-breast-cancer-survivors
[6] Using publicly available datasets to identify population-based transcriptomic landscape contributing to the aggressiveness of breast cancer in young women, OUCI. https://ouci.dntb.gov.ua/en/works/4aYAJEk4/
[7] Comparative analysis of breast cancer characteristics in young premenopausal and postmenopausal women in Ghana, Scientific Reports. https://library.nih.go.kr/ncmiklib/search/Retrieve.do?dbid=edssjs&an=edssjs.F77489D3
[8] Disparities in diagnosis, treatment, and outcomes of early-onset breast cancer: A global perspective, PubMed. https://pubmed.ncbi.nlm.nih.gov/41794162/
[9] Breast cancer in women under 45: Emerging trends and future directions, ScienceDirect. https://www.sciencedirect.com/science/article/pii/S2059702926012834
[10] Hormone receptor-positive early breast cancer in young women: A comprehensive review, ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S0305737224001324
[11] Fertility Preservation and Treatments for Patients With Breast Cancer: Yale’s Dr. Sarah Schellhorn, Yale School of Medicine. https://medicine.yale.edu/news-article/fertility-preservation-for-breast-cancer-patients/
[12] Contemporary Review of the Management and Treatment of Young Breast Cancer Patients, ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S1526820924001484
[13] Evaluating changes in the breast cancer-related quality of life of young women with breast cancer, UNAM. https://produccion.siia.unam.mx/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=695461
[14] Analysis the Burden of Breast Cancer Among Adolescents and Young Adults Using the Global Burden of Disease 2021, Springer. https://link.springer.com/article/10.1245/s10434-024-16648-0
[15] Breaking the Silence: Barriers to Fertility Preservation Among Young Breast Cancer Patients in Ghana – a multicenter study, PubMed. https://pubmed.ncbi.nlm.nih.gov/41333425/
[16] Clinical Characteristics and Long-Term Outcomes of Young Women With Breast Cancer: A Multicenter Study From Uruguay, PubMed. https://pubmed.ncbi.nlm.nih.gov/41853427/
[17] Clinico-Pathological Characteristics and Incidence Trends of Breast Cancer in Young Women, American Association for Cancer Research. https://aacrjournals.org/clincancerres/article-split/31/12_Supplement/P2-12-13/754038/
[18] Genetics and Inherited Risk, Young And Strong, Dana-Farber Cancer Institute. https://youngandstrong.dana-farber.org/resource/genetics-and-family-history/
[19] Fertility After Breast Cancer: What Are Your Options?, UPMC HealthBeat. https://share.upmc.com/2026/06/breast-cancer-fertility-options/
